CREATE Medicines closed a $122 million Series B round to advance in vivo CAR-T programs across autoimmune disease and oncology. The financing is aimed at progressing candidates built on the company’s mRNA-LNP platform, which directs immune reprogramming inside the body rather than manufacturing cells ex vivo. CREATE reported that it has dosed more than 50 patients across clinical programs and outlined expansion plans, including an autoimmune lead (CRT-402) and oncology programs such as MT-303. The company said the round extends runway without resetting strategy as clinical execution and data generation become the focus. The funding reinforces investor interest in repeat-dosing, off-the-shelf immune therapies and could accelerate competition among in vivo engineered-cell approaches.